Understanding genetic factors in heart damage from chemotherapy
Official title: Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs
Funded at Stanford University · NIH-10897272 · Data updated 2026-11-12
This study is looking at how your genes might affect the risk of heart damage from chemotherapy, especially from a drug called doxorubicin, and it aims to find ways to protect your heart during cancer treatment by creating heart cells that match your unique genetic makeup.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $131,973 |
| NIH project number | 5K99HL166773-02 |
| Project ID | NIH-10897272 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are at risk of developing heart problems due to chemotherapy, particularly those receiving doxorubicin.
✕Less likely to help
Patients who are not undergoing chemotherapy or those without genetic predispositions to cardiotoxicity may not benefit from this research.
What this research studies
This research investigates how genetic variations can influence the risk of heart damage caused by chemotherapy drugs, particularly doxorubicin. By using patient-specific induced pluripotent stem cells (iPSCs), the study aims to create heart cells that mimic the genetic makeup of individual patients. These cells will be used to identify specific genes that, when targeted, could help protect against heart damage during cancer treatment. The ultimate goal is to develop better risk assessment tools and therapies to prevent cardiotoxicity in cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatments that minimize heart damage for cancer patients undergoing chemotherapy.
How similar studies have gone: Previous research has shown promise in using iPSCs to study drug responses, indicating that this approach could yield valuable insights into cardiotoxicity.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Nishiga, Masataka — Stanford University
- Study coordinator: Nishiga, Masataka
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
-
PPAR-alpha and sex differences in chemotherapy-related heart injury
This project looks at why doxorubicin causes different heart side effects in men and women, and tests heart-protective ideas to help patients who need this chemotherapy.
-
Preventing heart damage from chemotherapy in older lymphoma patients
This study is looking to help older adults with lymphoma by finding ways to prevent heart damage from chemotherapy, figuring out who might be at risk, and understanding what patients and doctors prefer when it comes to treatment options.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.